News – Page 901 – Endpoints News

Sanifit touts positive PhIIb data; REGENXBIO licenses Clearside Biomedical tech

6 years ago

Buoyed by blockbuster Vertex payments, the CF Foundation seeds new advances with $500M fund

6 years ago

Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?

6 years ago

Peter Hecht’s Ironwood spinout fails back-to-back studies on a key drug, crushing shares and triggering cutbacks ...

6 years ago

Catalyst Pharma's Firdapse bet on congenital myasthenic syndromes turns sour

6 years ago

Amgen is joining the biopharma exodus out of neurosciences R&D, cutting 180 R&D jobs in reorganization

6 years ago

In a bid to get to Chinese patients faster, Shanghai's I-Mab plans $100M Nasdaq IPO

6 years ago

Why Scott Gottlieb, venture capitalist, sees opportunity in antibiotics

6 years ago

Novartis takes a hit as FDA orders a hold on Zolgensma trials in wake of fresh safety concerns

6 years ago

FDA experts vote to yank the agency's 2011 OK of controversial preterm birth drug after a trial failure

6 years ago

Hey, wait up Amgen and Mirati, Boehringer Ingelheim is joining the KRAS crowd as early success inspires rivals

6 years ago

TG Therapeutics touts safer PI3Kδ inhibitor as execs tout PhII data, hunt quick OK for a tough niche

6 years ago

Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T

6 years ago

GSK team clinches positive trial for the first potential new TB vaccine in a century — with millions of lives at ...

6 years ago

FDA drafts guidance on Type V DMFs for combination products

6 years ago

Novartis' $111M bet on IL-17C drug turns sour — but MorphoSys, Galapagos will explore options

6 years ago

Atlas, Novo-backed biotech reels in ex-Nimbus CEO Don Nicholson as exec chairman, hooks $50M to conquer anemia

6 years ago

Roche — surprise — delays $4.3B Spark buyout again as regulators hover

6 years ago

Boston jury finds biotech CEO guilty of fleecing investors, obstruction of justice

6 years ago

Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?

6 years ago

AstraZeneca’s triplet with Imfinzi, treme and chemo works on a key endpoint for frontline lung cancer

6 years ago

Here’s a new way to raise money for your biotech. This trailblazer came out $61M ahead with a place on the NYSE

6 years ago

FDA backs Mike Grey's bet on a comeback drug play with breakthrough status for maralixibat

6 years ago

Allergan ties up Namenda loose ends with $750M settlement

6 years ago

First page Previous page 898 899 900901902 903 904 Next page Last page